library.onepin.app/scopolamine-patch Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Cognitive & Mood

Cognitive & Mood Anticholinergic Prescription drug

Scopolamine Patch

Transderm Scop · Scopoderm · Scopolamine TTS

AnticholinergicAntiemeticMuscarinic receptor antagonistReservoir transdermal

Transderm-Scop (scopolamine patch) is a 3-day transdermal delivery system containing 1.5 mg scopolamine, releasing approximately 1 mg over 72 hours. Applied behind the ear on hairless skin, it is used primarily for prevention of motion sickness and post-operative nausea and vomiting. IMPORTANT: This is a RESERVOIR-type patch with a rate-controlling membrane - it must NEVER be cut, as cutting destroys the membrane and causes dose dump. Patch must be removed before MRI due to its metal backing.

Quick Start
Route
Transdermal Patch
Start low
1 mg over 3 days (one 1.5 mg patch)
Frequency
Every 3 days (72 hours)
Timing
Anytime

Apply behind one ear on hairless skin 4 hours before needed effect. Wash hands thoroughly after application to avoid eye contact (causes pupil dilation in the exposed eye).

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
1 mg over 3 days (one 1.5 mg patch) · Transdermal Patch · Every 3 days (72 hours)
Lowest starting point. Hold about a week to assess tolerance before stepping up.
1 mg over 3 days (one 1.5 mg patch)
Every 3 days (72 hours)
Standard
Motion Sickness Prophylaxis
1 mg (patch) · Topical · As needed
human clinical trial · FDA Transderm Scop label
1 mg (patch)
As needed
01

How it works

Scopolamine is a non-selective muscarinic acetylcholine receptor (mAChR) antagonist with activity at M1 receptors in the vestibular nuclei and vomiting center. By blocking cholinergic signaling in these central pathways, it dampens the nausea response to vestibular stimulation (motion) and interrupts afferent emetic signaling postoperatively. Its tertiary-amine structure allows it to cross the blood-brain barrier, giving it stronger central antiemetic effects than peripheral anticholinergics.

Scopolamine is a non-selective muscarinic acetylcholine receptor (mAChR) antagonist with activity at M1 receptors in the vestibular nuclei and vomiting center. By blocking cholinergic signaling in these central pathways, it dampens the nausea response to vestibular stimulation (motion) and interrupts afferent emetic signaling postoperatively. Its tertiary-amine structure allows it to cross the blood-brain barrier, giving it stronger central antiemetic effects than peripheral anticholinergics.

02

What to expect

Early
Days 1–7

0-4 hours: onset of effect

03

Evidence

HumanPresent
AnimalPresent
In-vitroPresent
2010Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis · Apfel CC, Zhang K, George E et al, Clinical Therapeutics ↗review
2011Scopolamine (hyoscine) for preventing and treating motion sickness · Spinks A, Wasiak J, Cochrane Database of Systematic Reviews ↗review
2006Transdermal scopolamine for prevention of motion sickness · Nachum Z, Shupak A, Gordon CR, Clinical Pharmacokinetics ↗review
2020The Effect of a Transdermal Scopolamine Patch on Postoperative Nausea and Vomiting after Retromastoid Craniectomy with Microvascular Decompression · Park JW, Min BG, Oh AY et al, Journal of Clinical Medicine ↗peer reviewed
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

Ondansetron (5-HT3 antagonist)Different mechanism - additive antiemetic effect in PONV.

Keep separate

Anticholinergic medications (antihistamines, TCAs, bladder antispasmodics)Additive anticholinergic burden - confusion, urinary retention, tachycardia. Especially risky in elderly users.
MAOIsTheoretical anticholinergic crisis. Avoid combination.
05

Side effects & safety

Commonly reported

  • Dry mouth (60-70%)
  • Blurred vision (mydriasis in exposed eye)
  • Drowsiness
  • Urinary retention

Less common & notes

  • Confusion (especially in elderly)
  • Hallucinations
  • Heat intolerance
  • Constipation
06

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~10 hours after patch removal
Peak · Tmax
Onset ~4 hours; full effect by 8 hours
Elimination
~24 hours after patch removal for full washout
Activity
72 hours per patch (every 3 days)

Storage. Store pouched patches at room temperature (20-25C). Apply immediately upon opening. Aluminized backing means patch must be removed before MRI.

07

Regulatory status

FDA-approved for motion sickness and PONV. Prescription-only. Classified as anticholinergic - avoid in narrow-angle glaucoma, urinary retention, pyloric stenosis.

Put it to work

Calculate, log & track

Open Scopolamine Patch straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Scopolamine Patch in the app →

Go deeper

The guide & community

The complete Scopolamine Patch walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community